Company: WHWK
Filing Date: 2025-04-25
Form Type: 424B5
Source: 0001193125-25-097064
Chunk: 0

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-04-25
Form: 424B5
Chunk 0
---
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-277018

PROSPECTUS SUPPLEMENT

(To Prospectus Supplements dated April 30, 2024

and May 3, 2024 and Prospectus dated April 30, 2024)

$75,000,000

Common Stock

This
prospectus supplement supplements the prospectus supplements dated April 30, 2024 and May 3, 2024 and the accompanying prospectus dated April 30, 2024 (collectively the “ATM Prospectus Supplement”), relating to the offer and
sales of shares of our common stock, par value $0.0001 per share, having an aggregate offering price of $13,500,000 pursuant to the terms of a sales agreement, as amended (the “sales agreement”), with TD Securities (USA) LLC, the successor
in interest to Cowen and Company, LLC (“TD Cowen”). Through the date hereof, we have not sold any shares of our common stock through TD Cowen under the ATM Prospectus Supplement. As of the filing of our Annual Report on Form 10-K on March 28, 2025, we are no longer limited by General Instruction I.B.6 of Form S-3 in the value of securities we may sell in a registered securities offering. In
accordance with the terms of the sales agreement, we may offer and sell shares of our common stock, having an aggregate offering price of up to $75,000,000 from time to time through TD Cowen acting as our agent under this prospectus supplement. This
prospectus supplement should be read in conjunction with the ATM Prospectus Supplement, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the ATM Prospectus
Supplement. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the ATM Prospectus Supplement, and any future amendments or supplements thereto.

Our common stock is listed on the Nasdaq Capital Market under the symbol “WHWK.” On April 24, 2025, the last reported sale price of our common stock on
the Nasdaq Capital Market was $1.51 per share.

Sales of our common stock, if any, under this prospectus supplement and the accompanying prospectus will be made in
negotiated transactions, including block trades or block sales, or at